#ASCO21: Eli Lilly-partnered Merus reveals new data for NRG1 fusion cancers including pancreatic and NSCLC

One of Eli Lilly’s newest R&D partners revealed some new data at #ASCO21 for an in-house program, and it’s one that could cover a broad range of solid tumors with rare genetic mutations.

The Dutch biotech Merus NV reported that their experimental drug zenocutuzumab, referred to as “zeno,” induced partial responses in 13 of 45 patients with NRG1 fusion-positive cancers as of April 13 cutoff date, good for an overall response rate of 29%. Merus is evaluating the candidate in a single-arm Phase I/II study with 61 enrolled patients.